Table 5 Multivariate analysis of recurrence-free survival at all Stages and Stage III
Variables | All Stages Hazard ratio ± SD (95% CI) | p-value | Stage III Hazard ratio ± SD (95% CI) | p-value |
|---|---|---|---|---|
Recurrence free suvival | ||||
ES vs SEMS | HR 0.42 ± 0.20 (0.03, 0.82) | 0.036 | HR 0.45 ± 0.26 (−0.04, 0.98) | 0.071 |
pT factor; T3/T4 | HR −0.55 ± 0.25 (−1.03, −0.06) | 0.089 | HR −0.51 ± 0.31 (−1.13, 0.13) | 0.258 |
pN factor; N0/N1/N2–3 | HR − 0.39 ± 0.29 (− 0.97, 0.14) | 0.364 | HR − 0.03 ± 0.23 (− 0.49, − 0.43) | 0.891 |
Verous invasion (v0–1/v2–3) | HR − 0.57 ± 0.19 (− 0.96, − 0.21) | 0.002 | HR −0.59 ± 0.24 (− 1.11, − 0.14) | 0.001 |
Lymphatic invasion (ly0–1/ly2–3) | HR 0.19 ± 0.22 (− 0.24, 0.64) | 0.396 | HR 0.01 ± 0.24 (− 0.40, 0.56) | 0.752 |
Overall suvival | ||||
ES vs SEMS | HR 0.86 ± 0.22 (0.42, 1.32) | < 0.001 | HR 0.99 ± 0.31 (0.40, 1.64) | < 0.001 |
pT factor; T3/T4 | HR −0.86 ± 0.28 (− 1.41, 0.31) | 0.007 | HR − 1.21 ± 0.40 (−2.03, − 0.42) | 0.019 |
pN factor; N0/N1/N2–3 | HR − 0.40 ± 0.30 (− 1.01, 0.18) | 0.358 | HR − 0.01 ± 0.24 (− 0.49, − 0.49) | 0.976 |
Verous invasion (v0–1/v2–3) | HR − 0.37 ± 0.20 (− 0.77, − 0.02) | 0.065 | HR −0.57 ± 0.27 (− 1.13, − 0.07) | 0.025 |
Lymphatic invasion (ly0–1/ly2–3) | HR 0.21 ± 0.23 (− 0.23, 0.69) | 0.348 | HR 0.29 ± 0.26 (− 0.21, 0.81) | 0.253 |